Skip to main content

Hydralazine Hcl

Brand names: Hydralazine Hcl

Arteriolar Vasodilator Oral

At a glance

Medicare prescriptions, 2024
5,243,483
Medicare drug cost
$71.5M
Average cost per prescription
$13.64
Clinicians who prescribed it
126,156

Where it is prescribed

Loading map…

List the prescribers in any state, county, city or ZIP code →

Trend, 2019–2024

Medicare prescriptions rose 14% from 2019 to 2024.

Medicare Part D prescriptions per year, all prescribers
  • 20195,315,413
  • 20205,377,525
  • 20215,457,026
  • 20225,598,574
  • 20235,806,142
  • 20246,072,709

Biggest change by state since 2019

  • Utah +39%
  • Puerto Rico +38%
  • Idaho +33%
  • Delaware +29%
  • Kansas +27%
  • Rhode Island (smallest change) −5%
  • North Dakota (smallest change) −3%

From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.

What it looks like

Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.

Directrx

StrengthLooks likeImprint
50 mgpink round tablet, 10 mmHP 3

Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc.

StrengthLooks likeImprint
10 mgpink round tablet, 6 mmEP 101
25 mgpink round tablet, 6 mmEP 102
50 mgpink round tablet, 8 mmEP 103
100 mgpink round tablet, 10 mmEP 104

Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.

Industry payments about this drug

No industry payments to clinicians named this drug in 2025.

Recalls and shortages

Not on the FDA drug shortage list.

No FDA-reported recalls since 2020.

Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.